Single Agent Abraxane as Second Line Therapy in Bladder Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00683059
Recruitment Status : Completed
First Posted : May 23, 2008
Last Update Posted : October 17, 2016
Celgene Corporation
Information provided by (Responsible Party):
Sunnybrook Health Sciences Centre

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : June 2012
  Study Completion Date : June 2012